Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 4/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29603695 | 0.92 | KMT2A (0.51) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL29697708 | 0.92 | KMT2A (0.51) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL8902890 | 0.92 | KMT2A (0.51) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL27637562 | 0.92 | KMT2A (0.51) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL1486191 | 0.88 | CASP3 (0.54) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL119400 | 0.88 | CASP3 (0.54) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL31610887 | 0.88 | CASP3 (0.54) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL29477078 | 0.88 | CASP3 (0.54) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL2551441 | 0.88 | CASP3 (0.54) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL1486209 | 0.88 | CASP3 (0.54) | KMT2ACASP3MDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116948008-A | Preparation method of salmon calcitonin | 上海苏豪逸明制药有限公司 | 2023-10-27 | — | — | CN | claimed |
| US-20230220000-A1 | PROCESS FOR PREPARING A GLP-1/GLUCAGON DUAL AGONIST | ELI LILLY AND COMPANY | 2023-07-13 | — | — | US | claimed |
| EP-4165058-A1 | PROCESS FOR PREPARING A GLP-1/GLUCAGON DUAL AGONIST | Eli Lilly and Company (US) | 2023-04-19 | — | — | EP | claimed |
| US-20230047729-A1 | METHOD FOR PREPARING LIRAGLUTIDE USING ENVIRONMENT-FRIENDLY SOLVENT | DAEBONG LS CO., LTD. (KR) | 2023-02-16 | — | — | US | claimed |
| EP-4116315-A1 | METHOD FOR PREPARING LIRAGLUTIDE USING ENVIRONMENT-FRIENDLY SOLVENT | Daebong LS Co., Ltd. (KR) | 2023-01-11 | — | — | EP | claimed |
| CN-113501871-B | Method for preparing darunavagon by combining solid phase with liquid phase | 汉肽生物医药集团有限公司 | 2022-10-28 | — | — | CN | claimed |
| US-12630601-B2 | Process for preparing a GIP/GLP1 dual agonist | ELI LILLY AND COMPANY (US) | 2026-05-19 | — | — | US | disclosed |
| US-12624079-B2 | Process for preparing a GIP/GLP1 dual agonist | ELI LILLY AND COMPANY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | CARMOT THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260035406-A1 | SYNTHESIS OF GLP-1R/GIPR AGONISTS | CARMOT THERAPEUTICS INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4685157-A2 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | Eli Lilly and Company (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4685156-A2 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | Eli Lilly and Company (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250382345-A1 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | LILLY CO ELI (US) | 2025-12-18 | — | — | US | disclosed |
| CN-113501871-B | Method for preparing darunavagon by combining solid phase with liquid phase | 汉肽生物医药集团有限公司 | 2022-10-28 | — | — | CN | disclosed |
| EP-3271398-B1 | ANTI-MUC16 ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-31 | — | — | EP | disclosed |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-07-26 | — | — | US | disclosed |
| CN-114573686-A | Polypeptide containing disulfide bond and having serine protease activity inhibition function and application thereof | 中国医学科学院药物研究所 | 2022-06-03 | — | — | CN | disclosed |
| CN-105017401-B | Purification method of ziconotide | 浙江和泽医药科技股份有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20220135639-A1 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | ELI LILLY AND COMPANY | 2022-05-05 | — | — | US | disclosed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | GLP1R, GIPR, CCKBR | KMT2A 2588/4885CASP3 3659/4885MDM4 4227/4885 |
| US-12624079-B2 | Process for preparing a GIP/GLP1 dual agonist | GLP1R, GIPR, GPR119 | KMT2A 953/4885CASP3 4346/4885MDM4 4723/4885 |
| US-12630601-B2 | Process for preparing a GIP/GLP1 dual agonist | GLP1R, GIPR, IAPP | KMT2A 633/4885CASP3 4745/4885MDM4 4345/4885 |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | GLP1R, IAPP, VIP | KMT2A 2915/4885CASP3 3093/4885MDM4 4464/4885 |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | GLP1R, IAPP, VIP | KMT2A 2915/4885CASP3 3093/4885MDM4 4464/4885 |
| US-20230220000-A1 | PROCESS FOR PREPARING A GLP-1/GLUCAGON DUAL AGONIST | GLP1R, GCGR, GCG | KMT2A 2195/4885CASP3 2562/4885MDM4 4762/4885 |
| US-20250382345-A1 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | GLP1R, GIPR, GPR119 | KMT2A 2749/4885CASP3 4305/4885MDM4 4854/4885 |
| US-20220135639-A1 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | GLP1R, GIPR, GPR119 | KMT2A 2749/4885CASP3 4305/4885MDM4 4854/4885 |
| US-20260035406-A1 | SYNTHESIS OF GLP-1R/GIPR AGONISTS | GLP1R, GIPR, GRPR | KMT2A 1129/4885CASP3 1940/4885MDM4 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.